170 related articles for article (PubMed ID: 27599572)
1. TAK1 inhibitor NG25 enhances doxorubicin-mediated apoptosis in breast cancer cells.
Wang Z; Zhang H; Shi M; Yu Y; Wang H; Cao WM; Zhao Y; Zhang H
Sci Rep; 2016 Sep; 6():32737. PubMed ID: 27599572
[TBL] [Abstract][Full Text] [Related]
2. Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis.
Wang H; Yu Y; Jiang Z; Cao WM; Wang Z; Dou J; Zhao Y; Cui Y; Zhang H
Sci Rep; 2016 May; 6():26456. PubMed ID: 27217076
[TBL] [Abstract][Full Text] [Related]
3. Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells.
Shi Y; Yu Y; Wang Z; Wang H; Bieerkehazhi S; Zhao Y; Suzuk L; Zhang H
Oncotarget; 2016 Nov; 7(45):73697-73710. PubMed ID: 27655642
[TBL] [Abstract][Full Text] [Related]
4. TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis.
Guan S; Lu J; Zhao Y; Woodfield SE; Zhang H; Xu X; Yu Y; Zhao J; Bieerkehazhi S; Liang H; Yang J; Zhang F; Sun S
Oncotarget; 2017 May; 8(20):33666-33675. PubMed ID: 28430599
[TBL] [Abstract][Full Text] [Related]
5. TAK1 ubiquitination regulates doxorubicin-induced NF-κB activation.
Liang L; Fan Y; Cheng J; Cheng D; Zhao Y; Cao B; Ma L; An L; Jia W; Su X; Yang J; Zhang H
Cell Signal; 2013 Jan; 25(1):247-54. PubMed ID: 22981905
[TBL] [Abstract][Full Text] [Related]
6. Nuclear factor-κB signaling inhibitors revert multidrug-resistance in breast cancer cells.
Abdin SM; Tolba MF; Zaher DM; Omar HA
Chem Biol Interact; 2021 May; 340():109450. PubMed ID: 33775688
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin induces atypical NF-κB activation through c-Abl kinase activity in breast cancer cells.
Esparza-López J; Medina-Franco H; Escobar-Arriaga E; León-Rodríguez E; Zentella-Dehesa A; Ibarra-Sánchez MJ
J Cancer Res Clin Oncol; 2013 Oct; 139(10):1625-35. PubMed ID: 23892407
[TBL] [Abstract][Full Text] [Related]
8. Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells.
Ku JM; Kim SR; Hong SH; Choi HS; Seo HS; Shin YC; Ko SG
Mol Cell Biochem; 2015 Nov; 409(1-2):33-43. PubMed ID: 26169986
[TBL] [Abstract][Full Text] [Related]
9. Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
Zhong T; Xu F; Xu J; Liu L; Chen Y
Biomed Pharmacother; 2015 Feb; 69():317-25. PubMed ID: 25661377
[TBL] [Abstract][Full Text] [Related]
10. Oestrogen treatment enhances the sensitivity of hormone-resistant breast cancer cells to doxorubicin.
Scherbakov AM; Lobanova YS; Andreeva OE; Shatskaya VA; Krasil'nikov MA
Biosci Rep; 2011 Apr; 31(2):137-43. PubMed ID: 20662767
[TBL] [Abstract][Full Text] [Related]
11. Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin-induced apoptosis.
Wang M; Liang L; Lu J; Yu Y; Zhao Y; Shi Z; Li H; Xu X; Yan Y; Niu Y; Liu Z; Shen L; Zhang H
Thorac Cancer; 2019 Apr; 10(4):918-929. PubMed ID: 30883017
[TBL] [Abstract][Full Text] [Related]
12. NG25, a novel inhibitor of TAK1, suppresses KRAS-mutant colorectal cancer growth in vitro and in vivo.
Ma Q; Gu L; Liao S; Zheng Y; Zhang S; Cao Y; Zhang J; Wang Y
Apoptosis; 2019 Feb; 24(1-2):83-94. PubMed ID: 30515612
[TBL] [Abstract][Full Text] [Related]
13. MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling.
McNew KL; Whipple WJ; Mehta AK; Grant TJ; Ray L; Kenny C; Singh A
Mol Cancer Res; 2016 Dec; 14(12):1204-1216. PubMed ID: 27655129
[TBL] [Abstract][Full Text] [Related]
14. TAK1 inhibitor 5Z-7-oxozeaenol sensitizes neuroblastoma to chemotherapy.
Fan Y; Cheng J; Vasudevan SA; Patel RH; Liang L; Xu X; Zhao Y; Jia W; Lu F; Zhang H; Nuchtern JG; Kim ES; Yang J
Apoptosis; 2013 Oct; 18(10):1224-34. PubMed ID: 23700229
[TBL] [Abstract][Full Text] [Related]
15. A Second-Generation Proteasome Inhibitor and Doxorubicin Modulates IL-6, pSTAT-3 and NF-kB Activity in MDA-MB-231 Breast Cancer Cells.
Vyas D; Lopez-Hisijos N; Shah P; Deshpande KS; Basson MD; Vyas A; Chaturvedi LS
J Nanosci Nanotechnol; 2017 Jan; 17(1):175-85. PubMed ID: 29617099
[TBL] [Abstract][Full Text] [Related]
16. Key role of nuclear factor-κB in the cellular pharmacokinetics of adriamycin in MCF-7/Adr cells: the potential mechanism for synergy with 20(S)-ginsenoside Rh2.
Zhang J; Lu M; Zhou F; Sun H; Hao G; Wu X; Wang G
Drug Metab Dispos; 2012 Oct; 40(10):1900-8. PubMed ID: 22745335
[TBL] [Abstract][Full Text] [Related]
17. Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects.
Li J; Wu Y; Wang D; Zou L; Fu C; Zhang J; Leung GP
Pharmacol Res; 2019 Aug; 146():104313. PubMed ID: 31202781
[TBL] [Abstract][Full Text] [Related]
18. Selective targeting of FAK-Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells.
Datta A; Bhasin N; Kim H; Ranjan M; Rider B; Abd Elmageed ZY; Mondal D; Agrawal KC; Abdel-Mageed AB
Cancer Lett; 2015 Jun; 362(1):25-35. PubMed ID: 25796439
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanism of suppression of MDR1 by puerarin from Pueraria lobata via NF-kappaB pathway and cAMP-responsive element transcriptional activity-dependent up-regulation of AMP-activated protein kinase in breast cancer MCF-7/adr cells.
Hien TT; Kim HG; Han EH; Kang KW; Jeong HG
Mol Nutr Food Res; 2010 Jul; 54(7):918-28. PubMed ID: 20077420
[TBL] [Abstract][Full Text] [Related]
20. NFκBP65 transcription factor modulates resistance to doxorubicin through ABC transporters in breast cancer.
Velaei K; Samadi N; Soltani S; Barazvan B; Soleimani Rad J
Breast Cancer; 2017 Jul; 24(4):552-561. PubMed ID: 27878697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
